MedTrace Logo

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

NCT01496391 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2014-04-09

No results posted yet for this study

Summary

Iodine-123 labelled ortho-Iodohippuric Acid (\[I-123\]-OIH) was used in the early 1970's as a kidney imaging agent or tracer that "lights-up" inside your body when scanned, but over the years its use has declined. The most commonly used tracer is Technetium-99m labelled Mercaptoacetyltriglycine (\[Tc-99m\]-Mertiatide or \[Tc-99m\]-MAG3). However, long-term shortages may threaten the supply of the radioactive substance Tc-99m in Canada and the world. As a result of such shortages, there is a need to identify other types of tracers that can be used for imaging. \[I-123\]-OIH may be an alternative.

The purpose of this study is to examine the diagnostic performance characteristics of \[I-123\]-OIH in comparison to \[Tc-99m\]-MAG3.

Conditions

  • Renal Function Impairment

Sponsors & Collaborators

  • McMaster University

    collaborator OTHER

  • St. Joseph's Healthcare Hamilton

    collaborator OTHER

  • Centre for Probe Development and Commercialization

    lead OTHER

Principal Investigators

  • Karen Gulenchyn, MD · St. Joseph's Healthcare Hamilton

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-05-31
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01496391 on ClinicalTrials.gov